Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

7.1%

6 terminated/withdrawn out of 84 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

38%

32 trials in Phase 3/4

Results Transparency

59%

32 of 54 completed trials have results

Key Signals

16 recruiting32 with results

Enrollment Performance

Analytics

Phase 3
29(37.2%)
Phase 2
23(29.5%)
Phase 1
22(28.2%)
Phase 4
3(3.8%)
Early Phase 1
1(1.3%)
78Total
Phase 3(29)
Phase 2(23)
Phase 1(22)
Phase 4(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (84)

Showing 20 of 84 trials
NCT07446439Phase 3Recruiting

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Role: lead

NCT06138613Phase 3Active Not Recruiting

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Role: lead

NCT07221578Phase 3Recruiting

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

Role: lead

NCT05366855Phase 3Terminated

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Role: lead

NCT05352893Phase 3Completed

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Role: lead

NCT03838926Phase 1Recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Role: lead

NCT06830044Phase 3Recruiting

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Role: lead

NCT07090161Phase 2Recruiting

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Role: lead

NCT07065773Phase 2Active Not Recruiting

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

Role: lead

NCT07362017Phase 3Not Yet Recruiting

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Role: lead

NCT06961968Phase 3Recruiting

Randomized Withdrawal Study in Patients With Schizophrenia

Role: lead

NCT04652882Phase 3Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

Role: lead

NCT06804603Phase 2Completed

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Role: lead

NCT07223632Phase 1Active Not Recruiting

Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient

Role: lead

NCT05922995Early Phase 1Terminated

The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)

Role: collaborator

NCT04856917Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Role: lead

NCT04697069Phase 2Terminated

A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

Role: lead

NCT04856930Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Role: lead

NCT06494397Phase 1Completed

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Role: lead

NCT07179055Phase 2Recruiting

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Role: lead